A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy

INTRODUCTION: Clinical trials confirmed the beneficial effects of adding pertuzumab (P) to the combination of trastuzumab-chemotherapy (TC) in the (neo)adjuvant setting of high-risk HER2-positive early breast cancer (HER2+BC). We evaluated the clinical, economic and societal impact of adding pertuzu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zambelli, Alberto, Cazzaniga, Marina, La Verde, Nicla, Munzone, Elisabetta, Antonazzo, Ippazio Cosimo, Mantovani, Lorenzo Giovanni, Di Cosimo, Serena, Mancuso, Anna, Generali, Daniele, Cortesi, Paolo Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428118/
https://www.ncbi.nlm.nih.gov/pubmed/37573652
http://dx.doi.org/10.1016/j.breast.2023.08.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428118/
https://www.ncbi.nlm.nih.gov/pubmed/37573652
http://dx.doi.org/10.1016/j.breast.2023.08.005

Ejemplares similares